MX2021012813A - Conjugados de citocina de liberacion lenta. - Google Patents
Conjugados de citocina de liberacion lenta.Info
- Publication number
- MX2021012813A MX2021012813A MX2021012813A MX2021012813A MX2021012813A MX 2021012813 A MX2021012813 A MX 2021012813A MX 2021012813 A MX2021012813 A MX 2021012813A MX 2021012813 A MX2021012813 A MX 2021012813A MX 2021012813 A MX2021012813 A MX 2021012813A
- Authority
- MX
- Mexico
- Prior art keywords
- slow release
- cytokine conjugates
- release cytokine
- conjugates
- releasable
- Prior art date
Links
- 102000004127 Cytokines Human genes 0.000 title abstract 2
- 108090000695 Cytokines Proteins 0.000 title abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nanotechnology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962839112P | 2019-04-26 | 2019-04-26 | |
| PCT/US2020/029911 WO2020219943A1 (en) | 2019-04-26 | 2020-04-24 | Slow-release cytokine conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021012813A true MX2021012813A (es) | 2022-03-17 |
Family
ID=72941771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021012813A MX2021012813A (es) | 2019-04-26 | 2020-04-24 | Conjugados de citocina de liberacion lenta. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220193253A1 (https=) |
| EP (1) | EP3958888A4 (https=) |
| JP (2) | JP7608360B2 (https=) |
| KR (1) | KR20220004134A (https=) |
| CN (1) | CN114126638A (https=) |
| AU (1) | AU2020261076B2 (https=) |
| BR (1) | BR112021021481A2 (https=) |
| CA (1) | CA3136726A1 (https=) |
| MX (1) | MX2021012813A (https=) |
| SG (1) | SG11202111175YA (https=) |
| WO (1) | WO2020219943A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240141853A (ko) | 2017-08-03 | 2024-09-27 | 신톡스, 인크. | 자가면역 질환의 치료를 위한 사이토카인 접합체 |
| SG11202102930YA (en) | 2018-11-08 | 2021-04-29 | Synthorx Inc | Interleukin 10 conjugates and uses thereof |
| EP3923974A4 (en) | 2019-02-06 | 2023-02-08 | Synthorx, Inc. | IL-2 CONJUGATES AND METHODS OF USE THEREOF |
| EP4017540A1 (en) | 2019-08-23 | 2022-06-29 | Synthorx, Inc. | Il-15 conjugates and uses thereof |
| US12234271B2 (en) | 2019-09-10 | 2025-02-25 | Synthorx, Inc. | Il-2 conjugates and methods of use to treat autoimmune diseases |
| CA3153644A1 (en) * | 2019-09-30 | 2021-04-08 | Beijing Xuanyi Pharmasciences Co., Ltd. | Protein-macromolecule conjugates and methods of use thereof |
| WO2022115563A1 (en) * | 2020-11-25 | 2022-06-02 | Prolynx Llc | Extended release hydrogel conjugates of c-natriuretic peptides |
| JP2024512761A (ja) * | 2021-03-29 | 2024-03-19 | オーディー セラピューティクス リミテッド | タンパク質－高分子コンジュゲートおよびその使用方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2295450B1 (en) * | 2000-09-29 | 2015-01-28 | Merck Sharp & Dohme Corp. | Pegylated interleukin-10 |
| US7910540B2 (en) * | 2004-06-10 | 2011-03-22 | Zymogenetics, Inc. | Soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners and methods of using in inflammation |
| ES2584381T3 (es) * | 2010-05-05 | 2016-09-27 | Prolynx Llc | Liberación controlada de compuestos activos desde conjugados macromoleculares |
| US8703907B2 (en) * | 2010-05-05 | 2014-04-22 | Prolynx Llc | Controlled drug release from dendrimers |
| EP2566334B1 (en) * | 2010-05-05 | 2018-04-18 | Prolynx, LLC | Controlled drug release from solid supports |
| CA2848142C (en) * | 2011-09-07 | 2021-05-18 | Prolynx Llc | Hydrogels with biodegradable crosslinking |
| US11401312B2 (en) * | 2013-04-19 | 2022-08-02 | Cytune Pharma | Cytokine derived treatment with reduced vascular leak syndrome |
| MA39711A (fr) * | 2014-04-03 | 2015-10-08 | Nektar Therapeutics | Conjugués d'une fraction d'il-15 et d'un polymère |
| AU2015301936B2 (en) * | 2014-08-11 | 2019-03-07 | Delinia, Inc. | Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases |
| MX2018007304A (es) * | 2015-12-21 | 2019-03-14 | Armo Biosciences Inc | Composiciones de interleucina-15 y sus usos. |
| KR20240141853A (ko) * | 2017-08-03 | 2024-09-27 | 신톡스, 인크. | 자가면역 질환의 치료를 위한 사이토카인 접합체 |
-
2020
- 2020-04-24 CN CN202080046706.5A patent/CN114126638A/zh active Pending
- 2020-04-24 CA CA3136726A patent/CA3136726A1/en active Pending
- 2020-04-24 KR KR1020217038681A patent/KR20220004134A/ko active Pending
- 2020-04-24 US US17/606,687 patent/US20220193253A1/en active Pending
- 2020-04-24 MX MX2021012813A patent/MX2021012813A/es unknown
- 2020-04-24 JP JP2021563306A patent/JP7608360B2/ja active Active
- 2020-04-24 SG SG11202111175YA patent/SG11202111175YA/en unknown
- 2020-04-24 BR BR112021021481A patent/BR112021021481A2/pt unknown
- 2020-04-24 AU AU2020261076A patent/AU2020261076B2/en active Active
- 2020-04-24 EP EP20795140.1A patent/EP3958888A4/en active Pending
- 2020-04-24 WO PCT/US2020/029911 patent/WO2020219943A1/en not_active Ceased
-
2024
- 2024-12-18 JP JP2024221659A patent/JP2025063045A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020261076B2 (en) | 2026-01-22 |
| JP7608360B2 (ja) | 2025-01-06 |
| CA3136726A1 (en) | 2020-10-29 |
| EP3958888A1 (en) | 2022-03-02 |
| SG11202111175YA (en) | 2021-11-29 |
| US20220193253A1 (en) | 2022-06-23 |
| JP2022530462A (ja) | 2022-06-29 |
| BR112021021481A2 (pt) | 2021-12-21 |
| WO2020219943A1 (en) | 2020-10-29 |
| AU2020261076A1 (en) | 2021-11-18 |
| EP3958888A4 (en) | 2023-07-12 |
| JP2025063045A (ja) | 2025-04-15 |
| CN114126638A (zh) | 2022-03-01 |
| KR20220004134A (ko) | 2022-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021012813A (es) | Conjugados de citocina de liberacion lenta. | |
| MX2020001270A (es) | Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39. | |
| BR112022012112A2 (pt) | Agonistas de il2 e métodos de uso dos mesmos | |
| WO2019173832A3 (en) | Cytokine prodrugs | |
| ZA202201874B (en) | Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies | |
| CL2017002422A1 (es) | Derivados de maitansinoide, conjugados de los mismos, y métodos de uso. | |
| CL2021000855A1 (es) | Replicones basados en alfavirus para la administración de bioterapias. | |
| CL2020002540A1 (es) | Anticuerpos anti-hla-g y utilización de los mismos | |
| MX390083B (es) | Formulaciones de (r)-2-amino-3-fenilpropil carbamato. | |
| CO2018003477A2 (es) | Anticuerpos anti-pd1 y métodos de uso | |
| ECSP21068097A (es) | Anticuerpos claudina 6 y usos de los mismos | |
| EP4335874A3 (en) | Anti-hla-g antibodies and use thereof | |
| EA202190974A1 (ru) | Противовирусные пролекарства и их наносоставы | |
| MX2025010681A (es) | Formulaciones transdermicas | |
| MX2019007554A (es) | Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso. | |
| BR112021011124A2 (pt) | Anelossomos e métodos de uso | |
| BR112018010279A2 (pt) | novos anticorpos anti-emr2 e métodos de uso | |
| MX377663B (es) | Intermediarios en la sintesis de eribulina y metodos de sintesis relacionados. | |
| MX2020011027A (es) | Constructos de anticuerpos biespecíficos trivalentes. | |
| MX2020009465A (es) | Anticuerpos anti-klk5 y metodos de uso. | |
| CL2019003557A1 (es) | Anticuerpos anti-trkb. | |
| MX2018007818A (es) | Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso. | |
| IL290231A (en) | Mhc class ii molecules and methods of use thereof | |
| BR112018012884A2 (pt) | novos anticorpos anti-mmp16 e métodos de uso | |
| CL2022001138A1 (es) | Anticuerpos tmem219 y usos terapéuticos de los mismos |